scleroderma and pulmonary hypertension

Systemic sclerosis, also known as scleroderma, is a rare autoimmune disorder marked by the thickening and hardening of skin and connective tissues in various organs. Pulmonary hypertension is a condition characterized by high blood pressure in the arteries of the lungs due to increased resistance in these vessels. There is a recognized association between systemic sclerosis and pulmonary hypertension, with individuals affected by scleroderma being at an elevated risk of developing pulmonary hypertension.

Among those with systemic sclerosis, lung involvement is a prevalent complication, with pulmonary hypertension being one of the most serious manifestations. The prevalence of pulmonary hypertension in this patient population is estimated to be between 10% and 15%, and it stands as one of the leading causes of mortality. Early signs of pulmonary hypertension can be subtle, but as the disease advances, symptoms such as shortness of breath, fatigue, and chest pain may become more pronounced. If left untreated, pulmonary hypertension can lead to right ventricular hypertrophy and eventually heart failure.

For individuals managing both systemic sclerosis and pulmonary hypertension, it is crucial to adopt and maintain healthy lifestyle practices. This includes abstaining from smoking, moderating alcohol intake, engaging in regular physical activity, and adhering to a balanced diet. Regular medical check-ups are also essential for the early detection and management of pulmonary hypertension and other potential complications. In terms of pharmacological treatment, it is imperative that patients follow the guidance of their healthcare provider and not self-administer medications without proper medical advice.